Medicaid rebates for brand-name drugs exceeded Part D rebates by a substantial margin.
- Physical Description: 1 online resource (12 pages) : color illustrations
- Publisher: [Washington, D.C.] : Department of Health and Human Services, Office of Inspector General, 2015.
|General Note:|| Title from title screen (viewed May 31, 2016).
|Bibliography, etc. Note:|| Includes bibliographical references.
Search for related items by subject
|Subject:||Medicare > Finance.
Medicaid > Finance.
Drugs > United States > Finance > Government policy.
Brand name products > United States > Costs.
Rebates > United States.
United States. Patient Protection and Affordable Care Act.